TABLE 3.
Characteristic | Univariate analysis
|
Multivariate analysis
|
||
---|---|---|---|---|
HR (95 % CI) | p value | HR (95 % CI) | p value | |
Age | 0.99 (0.98–1.01) | 0.32 | – | |
Male sex | 1.14 (0.78–1.67) | 0.50 | – | |
Tumor size | 1.04 (1.01–1.07) | 0.02 | 1.07 (1.01–1.13) | 0.03 |
Hormone functional | 1.64 (1.10–2.44) | 0.02 | 1.39 (0.78–2.50) | 0.26 |
Laterality | ||||
Left | Ref | – | ||
Right | 1.05 (0.72–1.52) | 0.82 | ||
T stage | ||||
T1/T2 | Ref | Ref | ||
T3/T4 | 1.91 (1.28–2.85) | 0.002 | 1.71 (0.84–3.49) | 0.14 |
Capsular invasion | 2.14 (1.32–3.49) | 0.002 | 2.36 (1.21–4.64) | 0.01 |
N stage | ||||
N0 | Ref | Ref | ||
N1 | 3.15 (1.52–6.52) | 0.002 | 1.93 (0.44–8.40) | 0.38 |
Nx | 1.14 (0.71–1.85) | 0.59 | 1.28 (0.59–2.78) | 0.53 |
Operation type | ||||
Open abdominal or posterior | Ref | – | ||
Minimally invasive Surgery | 0.72 (0.44–1.18) | 0.19 | ||
Thoracoabdominal surgery | 1.08 (0.64–1.85) | 0.76 | ||
Multiorgan resection | 1.20 (0.82–1.77) | 0.36 | – | |
Tumor rupture during surgery | 1.42 (0.76–2.68) | 0.27 | – | |
Margin | ||||
R0 | Ref | Ref | ||
R1 | 1.27 (1.01–1.60) | 0.04 | 0.85 (0.39–1.83) | 0.68 |
Neoadjuvant chemotherapy | 0.68 (0.09–4.86) | 0.70 | – | |
Adjuvants radiotherapy | 1.48 (0.74–2.96) | 0.27 | – | |
Adjuvant chemotherapy | 1.53 (0.90–2.61) | 0.12 | – | |
Adjuvant mitotane | 1.82 (1.16–2.80) | 0.006 | 1.43 (0.73–2.80) | 0.29 |
HR hazard ratio, CI confidence interval